1-1 of 1 results for subject:Pfizer
Librarians' tools
- Search time
- 0.168 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for International Trade, what steps the Government has taken in line with its support for voluntary licences to encourage (a) Pfizer and (b) Moderna to share their covid-19 vaccine technology with potential mRNA manufacturers across Africa, Latin America and Asia identified by MSF and...
To ask the Secretary of State for International Trade, what steps the Government has taken in line with its support for voluntary licences to encourage (a) Pfizer and (b) Moderna to share their covid-19 vaccine technology with potential mRNA manufacturers across Africa, Latin America and Asia identified by MSF and...
The role of the legal framework provided by the TRIPS Agreement has and will continue to provide innovators the confidence to invest in developing health products and technologies and to form collaborative partnerships. This is evidenced with over 300 successful voluntary licensing and technology transfer partnerships, which are contributing to the production of approximately 1.5 billion COVID-19 vaccine doses per month.
We encourage industry to continue forming voluntary licensing and technology transfer partnerships. Working with commercial partners within the existing international IP framework is the most effective way to make use of global capacity to produce life-saving medicines at pace.